Aurora, IL, USA, July 31, 2019 – Leading global food processor OSI and Impossible Foods, makers of the award-winning Impossible™ Burger, launched a co-manufacturing collaboration today.
Impossible Foods announced today that OSI will begin producing Impossible™ Burger at multiple OSI plants starting next month, and continue to expand production of Impossible Foods’ flagship product, the Impossible Burger, throughout 2019 and thereafter.
“As a leading global protein provider, OSI is proud to partner with Impossible Foods on production of alternative, plant-based proteins to meet the demands of a growing market in line with consumer trends,” said Kevin Scott, senior executive vice president, OSI North America. “We are a customer-centric company, and our mission is to supply our customers with world-leading protein products, working together to produce the best proteins for each market.”
OSI has extensive capabilities to source, develop, produce and distribute custom foods solutions worldwide. The privately held company based in Aurora, Illinois, has more than 65 facilities in 17 countries and regions.
“We conducted an exhaustive due diligence process to determine how to scale our manufacturing, and were thoroughly impressed with OSI’s commitment to quality and responsiveness,” said Impossible Foods Senior Vice President of Product and Operations Sheetal Shah.
As OSI expands its product offering to include alternative proteins, David McDonald, president and chief operating officer of OSI, reiterated OSI’s commitment to farmers around the world, saying, “Expanding into alternative proteins is an addition to our company’s product offering, not a replacement. OSI is committed to supporting sustainable farming and agriculture, and will continue to put sustainability for all our supply chains and operations at the forefront of our mission.”
About Impossible Foods:
Based in California’s Silicon Valley, Impossible Foods makes delicious, nutritious meat and dairy products from plants. The privately held company was founded in 2011 by Patrick O. Brown, M.D., Ph.D., Professor Emeritus of Biochemistry at Stanford University and a former Howard Hughes Medical Institute Investigator. Investors include Khosla Ventures, Bill Gates, Google Ventures, Horizon Ventures, UBS, Viking Global Investors, Temasek, Sailing Capital, and Open Philanthropy Project.